 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Journal: A randomised dose finding study of combination dronabinol and acetazolamide for the treatment of obstructive sleep apnoea. (Pubmed Central) - Nov 26, 2024
One week of nightly IHL-42X at low, medium, and high doses was well tolerated, safe and associated with significant reductions in OSA severity.
- || acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Enrollment closed, Trial completion date, Trial primary completion date: Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs (clinicaltrials.gov) - Nov 8, 2024
P1, N=116, Active, not recruiting, Sponsor: Incannex Healthcare Ltd
One week of nightly IHL-42X at low, medium, and high doses was well tolerated, safe and associated with significant reductions in OSA severity. Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
- || acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Trial primary completion date: Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs (clinicaltrials.gov) - May 6, 2024
P1, N=116, Recruiting, Sponsor: Incannex Healthcare Ltd
Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024 Trial primary completion date: Apr 2024 --> Jul 2024
- |||||| acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Enrollment open: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (clinicaltrials.gov) - May 5, 2024
P2/3, N=560, Recruiting, Sponsor: Incannex Healthcare Ltd
Trial primary completion date: Apr 2024 --> Jul 2024 Not yet recruiting --> Recruiting
- ||||| acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Trial initiation date: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (clinicaltrials.gov) - Mar 25, 2024
P2/3, N=560, Not yet recruiting, Sponsor: Incannex Healthcare Ltd
Not yet recruiting --> Recruiting Initiation date: Jan 2024 --> Apr 2024
- ||||| acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Trial completion date, Trial initiation date, Trial primary completion date: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (clinicaltrials.gov) - Dec 17, 2023
P2/3, N=560, Not yet recruiting, Sponsor: Incannex Healthcare Ltd
- || acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Trial completion date, Trial primary completion date: Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs (clinicaltrials.gov) - Nov 28, 2023
P1, N=116, Recruiting, Sponsor: Incannex Healthcare Ltd
- |||||||||| acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
New P2/3 trial: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (clinicaltrials.gov) - Nov 27, 2023
P2/3, N=560, Not yet recruiting, Sponsor: Incannex Healthcare Ltd
- ||| acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
Enrollment open, Trial initiation date: Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs (clinicaltrials.gov) - Oct 4, 2023
P1, N=116, Recruiting, Sponsor: Incannex Healthcare Ltd
Initiation date: Jan 2024 --> Apr 2024 Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Sep 2023
- | acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
New P1 trial: Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs (clinicaltrials.gov) - May 12, 2023
P1, N=116, Not yet recruiting, Sponsor: Incannex Healthcare Ltd
- acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
A Randomised Controlled Trial Examining the Combined Impact of Acetazolamide and Dronabinol for the Treatment of Obstructive Sleep Apnoea (Walter E. Washington Convention Center, Area K, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_7300;
Mechanistically, our findings suggest that IHL-42X works to improve OSA severity by lowering loop gain across all doses. The low dose of IHL-42X had an additional ability to reduce (i.e.
- | acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
$IXHL Incannex Expands Intellectual Property Position over IHL-42X https://t.co/ntVgZmtcBr (Twitter) - Dec 6, 2022
- | acetazolamide/tetrahydrocannabinol (IHL-42X) / Incannex
New P1/2 trial: An Open Label Extension on the Examination of the Combination of Dronabinol and Acetazolamide for Treatment of Obstructive Sleep Apnoea (OSA) (EUDRACT) - Aug 27, 2021
P1/2, N=12, Not yet recruiting, Sponsor: Incannex Healthcare Ltd